middle.news
Recce Pharmaceuticals Expands Phase 3 Trial Scope for Diabetic Foot Infections
10:03am on Monday 22nd of June, 2026 AEST
•
Healthcare
Read Story
Recce Pharmaceuticals Expands Phase 3 Trial Scope for Diabetic Foot Infections
10:03am on Monday 22nd of June, 2026 AEST
Key Points
HREC approval advances Australian Phase 3 trial to pivotal status
Patient eligibility expanded to include moderate diabetic foot infections
Inclusion of infected ulcers below the knee increases study power
Parallel Phase 3 trials in Australia and Indonesia underpin global strategy
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Recce Pharmaceuticals (ASX:RCE)
OPEN ARTICLE